Results 211 to 220 of about 2,318,494 (246)
Some of the next articles are maybe not open access.

Immune checkpoint inhibitors and vasculitis

Current Opinion in Rheumatology, 2020
Purpose of review Clinical use of immune checkpoint inhibitor (ICI) therapy has revolutionized the therapeutic landscape of cancer. By activating the immune system using monoclonal anti-CTLA-4 and PD(L)-1 antibodies, remission can be induced in previously terminal cancers. However, these breakthroughs come at a price.
Patrick, Boland   +2 more
openaire   +2 more sources

Immune checkpoint inhibitors in GBM

Journal of Neuro-Oncology, 2021
The purpose of this review is to summarize recent updates regarding immune checkpoint inhibitor therapy in GBM patients including updates in brain immunology, clinical trials, mechanisms of resistance, and biomarkers of response.PubMed was searched to identify recent relevant articles on immune checkpoint inhibitor therapy as it pertains to GBM ...
openaire   +2 more sources

Immune Checkpoint Inhibitor Toxicity

Current Oncology Reports, 2018
Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges ...
David J, Palmieri, Matteo S, Carlino
openaire   +2 more sources

Cardiotoxicity of Immune Checkpoint Inhibitors

Current Treatment Options in Cardiovascular Medicine, 2019
Immunotherapies, particularly immune checkpoint inhibitors (ICI), are revolutionary cancer therapies being increasingly applied to a broader range of cancers. Our understanding of the mechanism, epidemiology, diagnosis, and treatment of cardiotoxicity related to immunotherapies remains limited.
Lili, Zhang   +8 more
openaire   +2 more sources

Melanoma and Immune Checkpoint Inhibitors

Current Oncology Reports, 2018
Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue   +5 more
openaire   +2 more sources

Immune Checkpoint Inhibitors in Cholangiocarcinoma

Immunotherapy, 2023
Cholangiocarcinoma is an epithelial malignancy originating in the biliary tracts and frequently recurs even with surgical resection. Unresectable disease has a 5-year overall survival of less than 10%. Given this poor prognosis, additional therapies are urgently needed. Chemotherapy has been the mainstay of treatment for many years.
openaire   +2 more sources

Radiotherapy, immunity, and immune checkpoint inhibitors

The Lancet Oncology
Radiotherapy exerts immunostimulatory and immunosuppressive effects, both locally, within the irradiated tumour microenvironment, and systemically, outside the radiation field. Inspired by preclinical data that showed synergy between radiotherapy and immune checkpoint inhibitors, multiple clinical trials were initiated with the hypothesis that combined
Connor, Lynch   +2 more
openaire   +2 more sources

Immune checkpoint inhibitor myocarditis

Current Opinion in Cardiology, 2019
The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis.The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate ...
Jayant, Raikhelkar, Nir, Uriel
openaire   +2 more sources

Immune Checkpoint Inhibitors in Gliomas

Current Oncology Reports, 2017
Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective ...
Aaron C, Tan   +2 more
openaire   +2 more sources

The Broadening Scope of Oral Mucositis and Oral Ulcerative Mucosal Toxicities of Anticancer Therapies

Ca-A Cancer Journal for Clinicians, 2022
Stephen Sonis   +2 more
exaly  

Home - About - Disclaimer - Privacy